Therefore, GATA3 implementation enhances adipogenesis, modifies fat distribution, improves insulin sensitivity, and reduces obesity-related inflammation, supporting its therapeutic relevance in type 2 diabetes (T2D) pathology [19,20]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.